| Literature DB >> 19723499 |
Masakazu Terauchi1, Jau-Yi Li, Brahmchetna Bedi, Ki-Hyun Baek, Hesham Tawfeek, Sarah Galley, Linda Gilbert, Mark S Nanes, Majd Zayzafoon, Robert Guldberg, David L Lamar, Meredith A Singer, Timothy F Lane, Henry M Kronenberg, M Neale Weitzmann, Roberto Pacifici.
Abstract
Intermittent administration of parathyroid hormone (iPTH) is used to treat osteoporosis because it improves bone architecture and strength, but the underlying cellular and molecular mechanisms are unclear. Here, we show that iPTH increases the production of Wnt10b by bone marrow CD8+ T cells and induces these lymphocytes to activate canonical Wnt signaling in preosteoblasts. Accordingly, in responses to iPTH, T cell null mice display diminished Wnt signaling in preosteoblasts and blunted osteoblastic commitment, proliferation, differentiation, and life span, which result in decreased trabecular bone anabolism and no increase in strength. Demonstrating the specific role of lymphocytic Wnt10b, iPTH has no anabolic activity in mice lacking T-cell-produced Wnt10b. Therefore, T-cell-mediated activation of Wnt signaling in osteoblastic cells plays a key permissive role in the mechanism by which iPTH increases bone strength, suggesting that T cell osteoblast crosstalk pathways may provide pharmacological targets for bone anabolism.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19723499 PMCID: PMC2751855 DOI: 10.1016/j.cmet.2009.07.010
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287